Characteristics of patients that failed early on erlotinib.

<p>Characteristics of patients that failed early on erlotinib.</p

Common toxicities.

<p>Common toxicities.</p

Mutations found.

<p>Mutations found.</p

Survival outcome.

<p>Kaplan-Meier curves for overall and progression free survival of the FIELT cohort.</p

Flow diagram of enrolled patients.

<p><b>Abbreviations</b>: inv, invasive; N, nodal status.</p

Additional file 1: Table S1. of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Lists names and affiliations of local Institutional Review Boards and Independent Ethics Committees that approved the study. (PDF 211 kb

Additional file 2: Table S2. of Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study

Shows the countries and respective populations that were involved in AGO-OVAR 16. (DOC 28 kb